Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MC240502 In-home iNtraVesIcal ThErapy (INVITE) Study - A Phase Ib/II, Single-Arm Trial of Delivering Intravesical Therapy for Bladder Cancer in Patients' Homes

Next Previous
Trial Profile

MC240502 In-home iNtraVesIcal ThErapy (INVITE) Study - A Phase Ib/II, Single-Arm Trial of Delivering Intravesical Therapy for Bladder Cancer in Patients' Homes

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; BCG vaccine; Gemcitabine; Mitomycin
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Acronyms INVITE

Most Recent Events

  • 23 Apr 2025 Status changed from not yet recruiting to recruiting.
  • 15 Apr 2025 Planned initiation date changed from 1 Mar 2025 to 15 Apr 2025.
  • 12 Feb 2025 Planned initiation date changed from 6 Feb 2025 to 1 Mar 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top